methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins is recommended (class IA) for all adults 21 years or older with an LDL-C of 190 mg/dL or greater. Statin treatment appears to reduce mortality and result in cost savings for health systems.
3,4 Therefore, we sought to examine rates of statin prescription in patients screened for dyslipidemia to identify treatment gaps in a real-world contemporary setting.
Methods | For our analysis, we used a deidentified, cloudbased national clinical registry called Explorys (Explorys Inc) that encompasses data from inpatient and outpatient encounters from 360 medical centers in all 50 states. Use of the Explory registry has been deemed exempt from institutional review board approval by University Hospitals Cleveland Medical Center. We included all patients between age 20 and 75 years who had both LDL-C and pharmacy records reported be- Results | Of the 2 884 260 patients with a qualifying lipid analysis, 109 980 (3.8%) had an LDL-C of 190 mg/dL or greater. The statin prescription rate for patients with severe dyslipidemia but without diabetes or established ASCVD was 66% (41 750) and was comparable with the rates for others with single indications: 69% (183 740) for patients with diabetes but without ASCVD and 68% (207 050) for patients with ASCVD but without diabetes. Even with more severe elevations in LDL-C levels (LDL-C>250 mg/dL and LDL-C>300 mg/dL), 25% (1250) of patients were not prescribed a statin. However, the statin prescription rate for patients (aged 40-75 years) with LDL-C levels of 190 mg/dL or greater was higher if patients had additional statin indications ( Figure 1 ). The prescription rate for patients with LDL-C levels of 190 mg/dL or greater and diabetes or established ASCVD improved to 84% (22 610) and then to 93% (7380) when all 3 conditions coexisted. Notably, statin prescription rates for patients with severe dyslipidemia varied sharply by age, with significantly lower rates in younger patients (Figure 2) . For instance, statins were prescribed in only 32% (610), 47% (3440), and 61% (8650) P < .001), nonwhite race (AOR, 1.10; 95% CI, 1.07-1.14; P < .001), and self-pay status (AOR, 1.16; 95% CI, 1.10-1.23; P < .001).
Discussion | We sought to assess statin prescription rates among patients with severe dyslipidemia to identify barriers to AS-CVD prevention. The prescription rate for patients with a documented LDL-C level of 190 mg/dL or greater was 66% without ASCVD, but it was 84% for patients with severe dyslipidemia in a secondary prevention setting and 93% for patients with coexisting severe dyslipidemia, diabetes, and ASCVD. Furthermore, prescription rates were highly dependent on age (even after adjusting for other demographics), with less than 45% of patients younger than 40 years receiving a statin prescription. This finding has particular relevance given the early onset of ASCVD and cardiovascular death observed in familial hypercholesterolemia studies from the pre-statin era. 5 For this reason, for patients with primary LDL-C elevation level of 190 mg/dL or greater and who are 21 years or older, current guidelines recommend against the use of an ASCVD risk calculation, which could inappropriately lead to deferral of statin therapy for these high-risk patients. 6 Specific interventions that optimize the follow up of younger patients after lipid screening may be needed to realize the potential for improved survival and cost reduction associated with the treatment of severe dyslipidemia. Patients with low-density lipoprotein (LDL-C) levels of 190 mg/dL or greater (to convert LDL-C values to millimoles per liter, multiply by 0.0259) were analyzed on the basis of whether a 3-hydroxy-3 -methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor or statin was prescribed and were then stratified by age group and sex. Younger patients were less likely to be prescribed a statin.
